(Malignant Tumors) Developing Novel RAS Inhibitors Using Cell-Permeable Peptide Proteins

(Malignant Tumors) Developing Novel RAS Inhibitors Using Cell-Permeable Peptide Proteins

(Malignant Tumors) Developing Novel RAS Inhibitors Using Cell-Permeable Peptide Proteins

• May 19, 2021
• Read time: 1 minute

On May 4, 2021, Professor Hiroshi Ueda and colleagues from Gifu University's United Graduate School of Drug Development and Medical Information Research published a novel RAS inhibitor developed using cell-permeable peptide proteins in Cell Chemical Biology.

Because approximately 30% of malignant tumors have RAS protein mutations and activation, causing cancer cell proliferation and metastasis, inhibiting RAS could control cancer progression. Professor Hiroshi Ueda's team discovered cell-permeable peptide proteins that can penetrate cell membranes in the RAS binding domain, enhancing inhibition of RAS protein mutations. Currently, sotorasib targets KRAS G12C mutations. Beyond inhibiting G12C mutations, it has been confirmed to also inhibit RAS mutations such as G12V and G12D.

Future development will use sotorasib as a primary component, with various improvements to develop it as an innovative anti-cancer drug.

Source: https://medical-tribune.co.jp/news/2021/0512536365/

• Clinical Trial Medications

  (Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Phase 2 Trial Results. (Lung Cancer) HER2-Mutated Non-Small Cell Lung Cancer with Enhertu Effective? (Lung Cancer) Anti-B7-H3 Antibody Drug DS-7300 Effective?

Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1